The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8

M Filipits; M Rudas; V Kainz; CF Singer; F Fitzal; Z Bago-Horvath; Richard Greil; M Balic; P Regitnig; S Halper; W Hulla; D Egle; S Barron; T Loughman; D OxxxLeary; WM Gallagher; D Hlauschek; M Gnant; P Dubsky

doi:10.1158/1078-0432.CCR-21-1023

The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8

M Filipits, M Rudas, V Kainz, CF Singer, F Fitzal, Z Bago-Horvath, Richard Greil (Co-author), M Balic, P Regitnig, S Halper, W Hulla, D Egle, S Barron, T Loughman, D OxxxLeary, WM Gallagher, D Hlauschek, M Gnant, P Dubsky

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	5931-5938
Journal	CLINICAL CANCER RESEARCH
Volume	27
Issue number	21
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-1023
Publication status	Published - 2021

Keywords

PAM50 RISK
POSTMENOPAUSAL WOMEN
PROGNOSTIC INDEX
AUSTRIAN BREAST
TAMOXIFEN
SCORE
ANASTROZOLE
RECOMMENDATIONS
INFORMATION
SIGNATURE

Access to Document

10.1158/1078-0432.CCR-21-1023

Cite this

Filipits, M., Rudas, M., Kainz, V., Singer, CF., Fitzal, F., Bago-Horvath, Z., Greil, R., Balic, M., Regitnig, P., Halper, S., Hulla, W., Egle, D., Barron, S., Loughman, T., OxxxLeary, D., Gallagher, WM., Hlauschek, D., Gnant, M., & Dubsky, P. (2021). The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. CLINICAL CANCER RESEARCH , 27(21), 5931-5938. https://doi.org/10.1158/1078-0432.CCR-21-1023

Filipits, M ; Rudas, M ; Kainz, V et al. / The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. In: CLINICAL CANCER RESEARCH 2021 ; Vol. 27, No. 21. pp. 5931-5938.

@article{be67fd2db9904ae9b85f3768e473a4cc,

title = "The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8",

keywords = "PAM50 RISK, POSTMENOPAUSAL WOMEN, PROGNOSTIC INDEX, AUSTRIAN BREAST, TAMOXIFEN, SCORE, ANASTROZOLE, RECOMMENDATIONS, INFORMATION, SIGNATURE",

author = "M Filipits and M Rudas and V Kainz and CF Singer and F Fitzal and Z Bago-Horvath and Richard Greil and M Balic and P Regitnig and S Halper and W Hulla and D Egle and S Barron and T Loughman and D OxxxLeary and WM Gallagher and D Hlauschek and M Gnant and P Dubsky",

note = "[Greil, Richard] Paracelsus Med Univ, Salzburg Canc Res Inst, Canc Cluster Salzburg, Salzburg, Austria; ",

year = "2021",

doi = "10.1158/1078-0432.CCR-21-1023",

language = "English",

volume = "27",

pages = "5931--5938",

journal = "CLINICAL CANCER RESEARCH ",

issn = "1078-0432",

publisher = "Amer Assoc Cancer Research",

number = "21",

}

Filipits, M, Rudas, M, Kainz, V, Singer, CF, Fitzal, F, Bago-Horvath, Z, Greil, R, Balic, M, Regitnig, P, Halper, S, Hulla, W, Egle, D, Barron, S, Loughman, T, OxxxLeary, D, Gallagher, WM, Hlauschek, D, Gnant, M & Dubsky, P 2021, 'The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8', CLINICAL CANCER RESEARCH , vol. 27, no. 21, pp. 5931-5938. https://doi.org/10.1158/1078-0432.CCR-21-1023

The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. / Filipits, M; Rudas, M; Kainz, V et al.
In: CLINICAL CANCER RESEARCH , Vol. 27, No. 21, 2021, p. 5931-5938.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8

AU - Filipits, M

AU - Rudas, M

AU - Kainz, V

AU - Singer, CF

AU - Fitzal, F

AU - Bago-Horvath, Z

AU - Greil, Richard

AU - Balic, M

AU - Regitnig, P

AU - Halper, S

AU - Hulla, W

AU - Egle, D

AU - Barron, S

AU - Loughman, T

AU - OxxxLeary, D

AU - Gallagher, WM

AU - Hlauschek, D

AU - Gnant, M

AU - Dubsky, P

N1 - [Greil, Richard] Paracelsus Med Univ, Salzburg Canc Res Inst, Canc Cluster Salzburg, Salzburg, Austria;

PY - 2021

Y1 - 2021

KW - PAM50 RISK

KW - POSTMENOPAUSAL WOMEN

KW - PROGNOSTIC INDEX

KW - AUSTRIAN BREAST

KW - TAMOXIFEN

KW - SCORE

KW - ANASTROZOLE

KW - RECOMMENDATIONS

KW - INFORMATION

KW - SIGNATURE

U2 - 10.1158/1078-0432.CCR-21-1023

DO - 10.1158/1078-0432.CCR-21-1023

M3 - Original Article

C2 - 34380638

SN - 1078-0432

VL - 27

SP - 5931

EP - 5938

JO - CLINICAL CANCER RESEARCH

JF - CLINICAL CANCER RESEARCH

IS - 21

ER -

Filipits M, Rudas M, Kainz V, Singer CF, Fitzal F, Bago-Horvath Z et al. The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. CLINICAL CANCER RESEARCH . 2021;27(21):5931-5938. doi: 10.1158/1078-0432.CCR-21-1023